Programme

11th PACTRIMS Congress Themes:

  1. The Future of B-Cell Therapies in MS and NMOSD
  2. Targeting the Innate Immune System in PMS
  3. Development and Use of Biomarkers
  4. MRI Measures of Atrophy in the Clinic
Thursday, 1 November 2018
Grand Ballroom, Level B
13:00-14:30 European Charcot Foundation Symposium
14:30-15:00 Coffee Break
15:00-15:15 Opening Ceremony
15:15-17:10 Opening Lecture Series
Immune Mechanisms and Next Generation Therapies of MS and NMOSD
Opening Lecture-1
1. Landscape of B Cell Therapies and Possible Mechanisms of Action in MS
– TBA
Opening Lecture-2
2. Risks of Sustained B Cell Depletion
– Sean Riminton (Australia)
Opening Lecture-3
3. Emerging Treatment for NMOSD Based on Immune Mechanisms
– TBA
17:10-17:30 Coffee Break
17:30-19:00 Merck Sponsored Symposium
19:30-21:00 Welcome Reception

 

Friday, 2 November 2018
Grand Ballroom, Level B
08:00-09:30 Sanofi Genzyme Sponsored Symposium
09:30-10:00 Coffee Break
10:00 -11:30 Main Symposium-1
Surrogate Markers for Monitoring MS and NMOSD Disease Activity, Treatment Response, and Outcomes
1. Do Biomarkers Beget Better Biomarkers? (Serum and CSF Biomarkers)
– TBA
2. Do Clinicians Need to Monitor Atrophy Rates and What Factors Limit the Measurement of Atrophy Rates in the Clinic
– TBA
3. Passive and Active Monitoring Applications and Devices
– Helmut Butzkueven (Australia)
4. Artificial Intelligence in the Monitoring and Management of MS
– Fu-Dong Shi (China)
11:30-12:40 Oral Presentation
12:40-13:40 Lunch
13:40-14:20 11th PACTRIMS Presidential Invited Lecture
Innate Immune System-Mediated Mechanisms of action in Progressive MS: How to Target Innate Immunity in the Future
– TBA
14:20-14:50 Two Minute Oral Presentation of Selected Posters
14:50-15:10 Coffee Break
15:10-17:10 Main Symposium-2
Educational Seminars: Comprehensive Management of MS and NMOSD in Asia-Pacific Regions
1. Practical Issues in the Management of Relapsing Inflammatory CNS Disease in Asia-Pacific Regions
– Shanthi Viswanathan (Malaysia)
2. Aggressive MS & NMOSD: How to Define and How to Manage It
– Ho Jin Kim (Republic of Korea)
3. The Approach to the Management of Indeterminate MS/NMOSD
– Kazuo Fujihara (Japan)
4. Symptomatic Management of MS: What Works and What Doesn’t
– Simon Broadley (Australia)
17:10-17:30 Coffee Break
17:30-19:00 Biogen Sponsored Symposium
20:00-22:30 Presidential Dinner

 

Friday, 2 November 2018
Heritage Room, Level G (Breakout Session)
15:20-17:20 Main Symposium-3
Workshop: Potential Biomarkers Related to Mechanism of Inflammatory CNS Demyelinating Disease in Asians
1. CSF Biomarkers for NMOSD
– Shuhei Nishiyama (Japan)
2. Gamma Delta T Cells are Associated with Disability Progression in MS
– Noriko Isobe (Japan)
3. OCT and Eye Movements
– Owen White (Australia)

 

Saturday, 3 November 2018
Grand Ballroom, Level B
08:00-09:30 Roche Sponsored Symposium
09:30-10:00 Coffee Break
10:00-12:00 Main Symposium-4
New MRI Technology and Signs Disclose Pathology and Differentiation of MS and NMOSD
1. MRI Signs that Differentiate NMOSD from MS
– Yaou Liu (China)
2. Central Vein Sign Differentiates MS from CNS Vasculitis
– TBA
3. T1/T2-Weighted Ratio Disclose Cortical Pathology in MS
– TBA
4. MRI Neurography Reveals Peripheral Nerve Involvement in MS
– TBA
12:00-12:15 Closing and Award Ceremony

 

*subject to change